193 related articles for article (PubMed ID: 37574522)
1. Class switch towards spike protein-specific IgG4 antibodies after SARS-CoV-2 mRNA vaccination depends on prior infection history.
Kiszel P; Sík P; Miklós J; Kajdácsi E; Sinkovits G; Cervenak L; Prohászka Z
Sci Rep; 2023 Aug; 13(1):13166. PubMed ID: 37574522
[TBL] [Abstract][Full Text] [Related]
2. Appearance of tolerance-induction and non-inflammatory SARS-CoV-2 spike-specific IgG4 antibodies after COVID-19 booster vaccinations.
Akhtar M; Islam MR; Khaton F; Soltana UH; Jafrin SA; Rahman SIA; Tauheed I; Ahmed T; Khan II; Akter A; Khan ZH; Islam MT; Khanam F; Biswas PK; Ahmmed F; Ahmed S; Rashid MM; Hossain MZ; Alam AN; Alamgir ASM; Rahman M; Ryan ET; Harris JB; LaRocque RC; Flora MS; Chowdhury F; Khan AI; Banu S; Shirin T; Bhuiyan TR; Qadri F
Front Immunol; 2023; 14():1309997. PubMed ID: 38173725
[TBL] [Abstract][Full Text] [Related]
3. Cell immunity to SARS-CoV-2 after natural infection and/or different vaccination regimens.
Culebras E; Martínez M; Novella C; León JM; Marcos E; Delgado-Iribarren A; Ríos E
Front Cell Infect Microbiol; 2024; 14():1370859. PubMed ID: 38572317
[TBL] [Abstract][Full Text] [Related]
4. The appearance of anti-spike receptor binding domain immunoglobulin G4 responses after repetitive immunization with messenger RNA-based COVID-19 vaccines.
Yoshimura M; Sakamoto A; Ozuru R; Kurihara Y; Itoh R; Ishii K; Shimizu A; Chou B; Nabeshima S; Hiromatsu K
Int J Infect Dis; 2024 Feb; 139():1-5. PubMed ID: 38029832
[TBL] [Abstract][Full Text] [Related]
5. Assessment of humoral immune response to two mRNA SARS-CoV-2 vaccines (Moderna and Pfizer) in healthcare workers fully vaccinated with and without a history of previous infection.
Serrano L; Algarate S; Herrero-Cortina B; Bueno J; González-Barriga MT; Ducons M; Montero-Marco J; Acha B; Taboada A; Sanz-Burillo P; Yuste C; Benito R;
J Appl Microbiol; 2022 Sep; 133(3):1969-1974. PubMed ID: 35801660
[TBL] [Abstract][Full Text] [Related]
6. Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination.
Irrgang P; Gerling J; Kocher K; Lapuente D; Steininger P; Habenicht K; Wytopil M; Beileke S; Schäfer S; Zhong J; Ssebyatika G; Krey T; Falcone V; Schülein C; Peter AS; Nganou-Makamdop K; Hengel H; Held J; Bogdan C; Überla K; Schober K; Winkler TH; Tenbusch M
Sci Immunol; 2023 Jan; 8(79):eade2798. PubMed ID: 36548397
[TBL] [Abstract][Full Text] [Related]
7. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
8. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.
Bowman KA; Stein D; Shin S; Ferbas KG; Tobin NH; Mann C; Fischinger S; Ollmann Saphire E; Lauffenburger D; Rimoin AW; Aldrovandi G; Alter G
mBio; 2022 Oct; 13(5):e0164722. PubMed ID: 36000735
[TBL] [Abstract][Full Text] [Related]
9. Immune response kinetics to SARS-CoV-2 infection and COVID-19 vaccination among nursing home residents-Georgia, October 2020-July 2022.
Chisty ZA; Li DD; Haile M; Houston H; DaSilva J; Overton R; Schuh AJ; Haynie J; Clemente J; Branch AG; Arons MM; Tsang CA; Pellegrini GJ; Bugrysheva J; Ilutsik J; Mohelsky R; Comer P; Hundia SB; Oh H; Stuckey MJ; Bohannon CD; Rasheed MAU; Epperson M; Thornburg NJ; McDonald LC; Brown AC; Kutty PK
PLoS One; 2024; 19(4):e0301367. PubMed ID: 38625908
[TBL] [Abstract][Full Text] [Related]
10. The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients.
Fiorino F; Ciabattini A; Sicuranza A; Pastore G; Santoni A; Simoncelli M; Polvere J; Galimberti S; Baratè C; Sammartano V; Montagnani F; Bocchia M; Medaglini D
Front Immunol; 2022; 13():1017863. PubMed ID: 36248803
[TBL] [Abstract][Full Text] [Related]
11. Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization.
Fodor E; Olmos Calvo I; Kuten-Pella O; Hamar E; Bukva M; Madár Á; Hornyák I; Hinsenkamp A; Hetényi R; Földes F; Brigitta Z; Jakab F; Kemenesi G; Lacza Z
Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5297-5306. PubMed ID: 35916830
[TBL] [Abstract][Full Text] [Related]
12. Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm's COVID-19 Vaccines.
Adjobimey T; Meyer J; Sollberg L; Bawolt M; Berens C; Kovačević P; Trudić A; Parcina M; Hoerauf A
Front Immunol; 2022; 13():917905. PubMed ID: 35799790
[TBL] [Abstract][Full Text] [Related]
13. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
14. Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery.
Yang YJ; Murphy EA; Singh S; Sukhu AC; Wolfe I; Adurty S; Eng D; Yee J; Mohammed I; Zhao Z; Riley LE; Prabhu M
Obstet Gynecol; 2022 Mar; 139(3):373-380. PubMed ID: 34963127
[TBL] [Abstract][Full Text] [Related]
15. The Anti-SARS-CoV-2 IgG1 and IgG3 Antibody Isotypes with Limited Neutralizing Capacity against Omicron Elicited in a Latin Population a Switch toward IgG4 after Multiple Doses with the mRNA Pfizer-BioNTech Vaccine.
Espino AM; Armina-Rodriguez A; Alvarez L; Ocasio-Malavé C; Ramos-Nieves R; Rodriguez Martinó EI; López-Marte P; Torres EA; Sariol CA
Viruses; 2024 Jan; 16(2):. PubMed ID: 38399963
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Kinetics of Antibody Avidity and IgG Subclasses' Response in Patients with COVID-19 and Healthy Individuals Vaccinated with the BNT162B2 (Comirnaty, Pfizer/BioNTech) mRNA Vaccine.
Rastawicki W; Gierczyński R; Zasada AA
Viruses; 2023 Apr; 15(4):. PubMed ID: 37112950
[TBL] [Abstract][Full Text] [Related]
17. mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine.
Buhre JS; Pongracz T; Künsting I; Lixenfeld AS; Wang W; Nouta J; Lehrian S; Schmelter F; Lunding HB; Dühring L; Kern C; Petry J; Martin EL; Föh B; Steinhaus M; von Kopylow V; Sina C; Graf T; Rahmöller J; Wuhrer M; Ehlers M
Front Immunol; 2022; 13():1020844. PubMed ID: 36713457
[TBL] [Abstract][Full Text] [Related]
18. Analysis of IgG, IgA and IgM antibodies against SARS-CoV-2 spike protein S1 in convalescent and vaccinated patients with the Pfizer-BioNTech and CanSinoBio vaccines.
Melgoza-González EA; Hinojosa-Trujillo D; Reséndiz-Sandoval M; Mata-Haro V; Hernández-Valenzuela S; García-Vega M; Bravo-Parra M; Arvizu-Flores AA; Valenzuela O; Velázquez E; Soto-Gaxiola A; Gómez-Meza MB; Pérez-Jacobo F; Villela L; Hernández J
Transbound Emerg Dis; 2022 Jul; 69(4):e734-e745. PubMed ID: 34655457
[TBL] [Abstract][Full Text] [Related]
19. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
[TBL] [Abstract][Full Text] [Related]
20. Defining Clinical and Immunological Predictors of Poor Immune Responses to COVID-19 mRNA Vaccines in Patients with Primary Antibody Deficiency.
Shin JJ; Par-Young J; Unlu S; McNamara A; Park HJ; Shin MS; Gee RJ; Doyle H; Afinogenova Y; Zidan E; Kwah J; Russo A; Mamula M; Hsu FI; Catanzaro J; Racke M; Bucala R; Wilen C; Kang I
J Clin Immunol; 2022 Aug; 42(6):1137-1150. PubMed ID: 35713752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
